Institute of Pathology

A20 as a novel prognostic factor for recurrence and patients' survival in oral squamous cell carcinoma (2021) Spörl S, Erber R, Gerken M, Fischer R, Taxis J, Meier JK, Geppert CI, et al. Conference contribution Beta-HCG elevation as first sign of a malignant somatic transformation of a non-seminomatous germ cell tumor (2021) Peuser M, Hartmann A, Schmidt D, Mackensen A, Meidenbauer N Conference contribution Essential role of DNA-PKcs and plasminogen for the development of doxorubicin-induced glomerular injury in mice (2021) Bohnert BN, Gonzalez-Menendez I, Dörffel T, Schneider JC, Xiao M, Janessa A, Kalo MZ, et al. Journal article Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer-A Europe-Wide External Quality Assessment (2021) Erber R, Hartmann A, Fasching P, Rübner M, Stöhr R, Beckmann M, Zentgraf M, et al. Journal article Primary renal synovial sarcoma; a clinicopathological study of 19 cases comparing diagnostic utility of SS18-SSX-specific antibody with TLE1 (2021) Din NU, Fatima S, Hartmann A, Agaimy A Conference contribution IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies Forty Molecularly Homogenous and Histologically Variable Cases With Favorable Outcome (2021) Gloss S, Jurmeister P, Thieme A, Schmid S, Cai WY, Serrette RN, Perner S, et al. Journal article ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review (2021) Agaimy A, Baneckova M, Ihrler S, Müller SK, Franchi A, Hartmann A, Stöhr R, Skalova A Journal article, Review article Deep learning for diagnosis and survival prediction in soft tissue sarcoma (2021) Foersch S, Eckstein M, Wagner DC, Gach F, Woerl AC, Geiger J, Glasner C, et al. Journal article A novel urinary proteomics classifier for non-invasive evaluation of interstitial fibrosis and tubular atrophy in chronic kidney disease (2021) Catanese L, Siwy J, Mavrogeorgis E, Amann KU, Mischak H, Beige J, Rupprecht H Journal article CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma (2021) Klümper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, Rehlinghaus M, Hoffmann MJ, et al. Journal article